Пять молекул для таргетной биологической терапии тяжелой бронхиальной астмы: реалии и перспективы


DOI: https://dx.doi.org/10.18565/therapy.2020.5.195-205

А.Г. Малявин, И.Е. Козулина, Ю.А. Шарапова

1) ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России; 2) АО «ГлаксоСмитКляйн Трейдинг», г. Москва; 3) ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н. Бурденко» Минздрава России
Биологическая терапия открыла новую эру в лечении пациентов с тяжелой бронхиальной астмой. Сегодня существует уже 5 молекул, действующих на разные звенья патогенеза этого заболевания. В статье приведены данные о всех существующих ныне биологических таргетных препаратах, результаты основных клинических исследований, позволяющие оценить их эффективность и безопасность, а также данные о приоритетных направлениях клинических исследований.
Ключевые слова: тяжелая бронхиальная астма, Т2-фенотип, Т2-астма, эозинофилия, FeNO, IgE, омализумаб, реслизумаб, меполизумаб, бенрализумаб, дупилумаб, таргетная терапия, биологическая терапия
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Agache I., Beltran J., Akdis C. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75: 1023–42. doi: 10.1111/all.14221.

  2. Papi A., Brightling C., Pedersen S.E., Reddel H.K. Asthma. Lancet. 2018; 391(10122): 783–800. doi: 10.1016/S0140-6736(17)33311-1.

  3. Settipane R.A., Kreindler J.L., Chung Y., Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol. 2019; 123(6): 564–72.e3. doi: 10.1016/j.anai.2019.08.462.

  4. Perez de Llano L., Martinez-Moragon E., Plaza Moral V. et al. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. Respir Med. 2019; 151: 49–54. doi: 10.1016/j.rmed.2019.03.006.

  5. Chung K.F., Wenzel S.E., Brozek J.L. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43(2): 343–73. doi: 10.1183/09031936.00202013.

  6. Caminati M., Cegolon L., Vianello A. et al. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. Expert Rev Respir Med. 2019; 13(12): 1205–12. doi: 10.1080/17476348.2019.1676734.

  7. Fahy J.V. Type 2 inflammation in asthma – present in most, absent in many. Nat Rev Immunol. 2015; 15(1): 57–65. doi: 10.1038/nri3786.

  8. Seys S.F., Scheers H., Van den Brande P. et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res. 2017; 18(1): 39. doi: 10.1186/s12931-017-0524-y.

  9. Karlen S., De Boer M.L., Lipscombe R.J. et al. Biological and molecular characteristics of interleukin-5 and its receptor. Int Rev Immunol. 1998; 16 (3–4): 227–47. doi: 10.3109/08830189809042996.

  10. Gour N., Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015; 75(1): 68–78. doi: 10.1016/j.cyto.2015.05.014.

  11. Corren J. New targeted therapies for uncontrolled asthma. J Allergy Clin Immunol Pract. 2019; 7(5): 1394–403. doi: 10.1016/j.jaip.2019.03.022.

  12. Froidure A., Mouthuy J., Durham S. et al. Asthma phenotypes and IgE-responses. Eur Respir J. 2016; 47(1): 304–19. doi: 10.1183/13993003.01824-2014

  13. Wu L.C., Zarrin A.A. The production and regulation of IgE by the immune system. Nat Rev Immunol. 2014; 14(4): 247–59. doi: 10.1038/nri3632.

  14. Kawakami T., Blank U. From IgE to omalizumab. J Immunol. 2016; 197(11): 4187–92. doi:10.4049/jimmunol.1601476.

  15. Fajt M.L., Wenzel S.E. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015; 135(2): 299–310; quiz 311. doi: 10.1016/j.jaci.2014.12.1871.

  16. Busse W., Corren J., Lanier B.Q. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108(2): 184–90. doi: 10.1067/mai.2001.117880.

  17. Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013; 107(8): 1141–51. doi: 10.1016/j.rmed.2013.04.017.

  18. Samitas K., Radinger M., Bossios A. Current update on eosinophilic lung diseases and anti-IL-5 treatment. Recent Pat Antiinfect Drug Discov. 2011; 6(3): 189–205. doi: 10.2174/157489111796887855.

  19. Walsh G.M. An update on emerging drugs for asthma. Expert Opin Emerg Drugs. 2012; 17(1): 37–42. doi: 10.1517/14728214.2012.657625.

  20. Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371(13): 1189–97. doi: 10.1056/NEJMoa1403291.

  21. Ortega H.G., Yancey S.W., Mayer B. et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4(7): 549–56. doi: 10.1016/S2213-2600(16)30031-5.

  22. Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. Lancet Respir Med. 2015; 3(5): 355–66. doi: 10.1016/S2213-2600(15)00042-9.

  23. Khatri S., Moore W., Gibson P.G. et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019; 143(5): 1742–51.e7. doi: 10.1016/j.jaci.2018.09.033.

  24. Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: A multi-center, open-label, phase IIIb study. Clin Ther. 2016; 38(9): 2058–70.e1. doi: 10.1016/j.clinthera.2016.07.010.

  25. Difficult-to-treat and severe asthma in adolescence and adult patients. Diagnosis and management. GINA. V 2.0 April 2019. Available at: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf (date of access – 01.08.2020).

  26. Chapman K.R., Albers F.C., Chipps B. et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019; 74(9): 1716–26. doi: 10.1111/all.13850.

  27. Li J., Wang F., Lin C. et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: a systematic review and meta-analysis. J Asthma. 2017; 54(3): 300–07. doi: 10.1080/02770903.2016.1212371.

  28. Weinstein S., Katial R., Bardin F. et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2019; 7(2): 589–96. doi: 10.1016/j.jaip.2018.08.021.

  29. Deeks E.D., Brusselle G. Reslizumab in eosinophilic asthma: a review. Drugs. 2017; 77(7): 777–84. doi: 10.1007/s40265-017-0740-2.

  30. Tian B.P., Zhang G.S., Lou J. et al. Efficacy and safety of benralizumab for eosinophilic asthma: a systematic review and meta-analysis of randomized controlled trials. J Asthma. 2018; 55(9): 956–65. doi: 10.1080/02770903.2017.1379534.

  31. Goldman M., Hirsch I., Zangrilli J.G. et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017; 33(9): 1605–13. doi: 10.1080/03007995.2017.1347091.

  32. Nair P., Wenzel S., Rabe K. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017; 376(25): 2448–58. doi: 10.1056/NEJMoa1703501.

  33. Liu W., Ma X., Zhu W. Adverse events of benralizumab in moderate to severe eosinophilic asthma. A meta-analysis. Medicine. 2019; 98(22): e15868. doi: 10.1097/MD.0000000000015868.

  34. Wenzel S., Castro M., Corren J. et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016; 388(10039): 31–44. doi: 10.1016/S0140-6736(16)30307-5.

  35. Rabe K.F., Nair P., Brusselle G. et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018; 378(26): 2475–85. doi: 10.1056/NEJMoa1804093.

  36. Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2 agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388(10056): 2115–27. doi: 10.1016/S0140-6736(16)31324-1.

  37. FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388(10056): 2128–41. doi: 10.1016/S0140-6736(16)31322-8.

  38. Castro M., Corren J., Pavord I.D. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; 378(26): 2486–96. doi: 10.1056/NEJMoa1804092.

  39. Chupp G.L., Bradford E.S., Albers F.C. et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017; 5(5): 390–400. doi: 10.1016/S2213-2600(17)30125-X.

  40. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13): 1198–207. doi: 10.1056/NEJMoa1403290.

  41. Krings J.G., McGregor M.C., Bacharier L.B., Castro M. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol Pract. 2019; 7(5): 1379–92. doi: 10.1016/j.jaip.2019.03.008.

  42. Ando K., Tanaka A., Sagara H. Comparative efficacy and safety of dupilumab and benralizumab in patients with inadequately controlled asthma: a systematic review. Int J Mol Sci. 2020; 21(3): 889. doi: 10.3390/ijms21030889.

  43. Higgins J.P., Altman D.G., Gotzsche P.C. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928. doi: 10.1136/bmj.d5928.

  44. ClinicalTrial.gov. https://clinicaltrials.gov/


Об авторах / Для корреспонденции

Андрей Георгиевич Малявин, д.м.н., профессор, профессор кафедры фтизиатрии и пульмонологии лечебного факультета ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, генеральный секретарь РНМОТ, главный внештатный специалист-пульмонолог ЦФО Минздрава России. Адрес: 107150, г. Москва, ул. Лосиноостровская, д. 39, стр. 2. Тел.: 8 (916) 547-83-73.
E-mail: maliavin@mail.ru
Ирина Евгеньевна Козулина, к.м.н., медицинский советник АО «ГлаксоСмитКляйн Трейдинг». Адрес: 125167,
г. Москва, Ленинградский проспект, д. 37А, к. 4
Юлия Анатольевна Шарапова, к.м.н., главный терапевт департамента здравоохранения Воронежской области, доцент кафедры госпитальной терапии и эндокринологии ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н. Бурденко» Минздрава России. Адрес: 394066, г. Воронеж, Московский пр-т, д. 151

К содержанию номера

Бионика Медиа